IE48175B1 - N-(tetrazol-5-yl)prostaglandin carboxamides - Google Patents
N-(tetrazol-5-yl)prostaglandin carboxamidesInfo
- Publication number
- IE48175B1 IE48175B1 IE60/79A IE6079A IE48175B1 IE 48175 B1 IE48175 B1 IE 48175B1 IE 60/79 A IE60/79 A IE 60/79A IE 6079 A IE6079 A IE 6079A IE 48175 B1 IE48175 B1 IE 48175B1
- Authority
- IE
- Ireland
- Prior art keywords
- alpha
- tetrazol
- class
- trans
- compounds
- Prior art date
Links
- -1 prostaglandin carboxamides Chemical class 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 18
- 239000001257 hydrogen Substances 0.000 claims abstract description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000005977 Ethylene Substances 0.000 claims abstract description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000004305 biphenyl Substances 0.000 claims abstract description 3
- 235000010290 biphenyl Nutrition 0.000 claims abstract description 3
- 125000000068 chlorophenyl group Chemical group 0.000 claims abstract description 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 abstract description 18
- 230000035558 fertility Effects 0.000 abstract description 9
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract description 7
- 229940124630 bronchodilator Drugs 0.000 abstract description 6
- 125000001424 substituent group Chemical group 0.000 abstract description 6
- 230000000767 anti-ulcer Effects 0.000 abstract description 5
- 230000004071 biological effect Effects 0.000 abstract description 5
- 125000003944 tolyl group Chemical group 0.000 abstract description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 description 49
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 32
- 239000007858 starting material Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 238000002390 rotary evaporation Methods 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- QDMPKKFNRFFSNK-UHFFFAOYSA-N n-(2h-tetrazol-5-yl)formamide Chemical group O=CNC1=NN=NN1 QDMPKKFNRFFSNK-UHFFFAOYSA-N 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 239000003810 Jones reagent Substances 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000000741 diarrhetic effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 3
- SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 102100034195 Thrombopoietin Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000003699 antiulcer agent Substances 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003536 tetrazoles Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- AKNUHUCEWALCOI-UHFFFAOYSA-N N-ethyldiethanolamine Chemical compound OCCN(CC)CCO AKNUHUCEWALCOI-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- VTHIKKVKIVQWHV-UHFFFAOYSA-N chromium(6+) oxygen(2-) pyridine Chemical compound [O-2].[O-2].[O-2].[Cr+6].C1=CC=NC=C1 VTHIKKVKIVQWHV-UHFFFAOYSA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000524 functional group Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 description 1
- 125000003259 prostaglandin group Chemical group 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- JJPVWQWOOQYHCB-UHFFFAOYSA-N triethyl(phenyl)azanium Chemical compound CC[N+](CC)(CC)C1=CC=CC=C1 JJPVWQWOOQYHCB-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides compounds of the formula or pharmacologically acceptable salts thereof, wherein: A is ethylene of cis-vinylene; B is ethylene trans-vinylene; Y is hydrogen or hydroxy; G is CH2Ar, CH2OAr or CRZ(CH2)3CH3; Ar is phenyl, fluorophenyl, chlorophenyl, methylphenyl, ethylphenyl, methoxyphenyl, ethoxyphenyl, biphenyl or trifluoromethylphenyl; R is hydrogen or methyl; and Z is hydrogen or methyl. These compounds can be divided into three classes, each class having different and selective biological activities depending on the substituent in the bottom side chain. Compounds having a C-16 phenyl or substituted phenyl substituent have antiulcer activity, compounds having a C-16 phenoxy or substituted phenoxy substituent have fertility control activity and compounds having a C-15 n-pentyl, 1-methylpentyl, or 1,1-dimethylpentenyl substituent have bronchodilator or fertility control activity.
Description
The prostaglandins are C-20 unsaturated fatty acids which exhibit diverse physiological effects. Their structure, nomenclature, biological activities and medicinal use have been described in U.S. 3,971,825 and
U.S. 3,984,400.
A common problem confronting medical scientists who attempt to make biologically efficacious, synthetic drugs is the modulation of the biological action of an appropriate lead compound. In a traditional approach to drug synthesis the researcher will look for an increase in biological potency. The prostaglandin researcher however frames his design around increased oral activity, increased duration of action and enhancment of one of the diverse physiological effects of the prostaglandin class and diminution of the others. This latter criterion is important because without it a synthetic prostaglandin would exhibit incompatible side effects. For example it would be clinically inadvisable to administer an antiulcer synthetic prostaglandin that also causes diarrhea.
To achieve increased selectivity, researchers have concentrated their efforts on the active sites of the natural prostaglandins. In the main, these include the C-l carboxylic acid group, the C-9 ketone or hydroxyl group, the C-ll hydroxyl group and the lipophilic end of the bottom side chain. Such work is publicized in the following articles and patents: U.S. 4,011,262, U.S.
4,024,179, U.S. 3,971,826, O.S. 3,932,389, O.S. 3,974,213, O.S. 3,054,741, O.S, 3,987,087 Netherlands Octooraanvrage No. 7,306,030, B. J. Mayerlein, et al., Prostaglandins,
4, (1973) and W. Lipmann, Prostaglandins, T_, 231 (1974).
It has now been surprisingly discovered that an increase in the distance between the C-9 functionality and the top side chain acidic group by juncture of an amide group results in potent biological activity.
Three classes of C-1 amidotetrazole prostaglandins have been invented which have distinctly different profiles of biological activity. Class 1 includes compounds of formula 1, which have antiulcer activity.
H
Class 2 includes compounds of formula fertility control activity.
2, which have
H
Class 3 includes compounds of formula 3, which have bronchodilator or fertility control activity depending on the identity of R and Z.
4817S
It is apparent that the structural differentiation of the classes is found in the identity of the omega or bottom side chain. However, it is the combination of this functional group with the other important ones such as the amidotetrazole group that causes the different biological activities observed. Nevertheless, these three classes may be structurally combined into one generic formula (4).
Generic Formula 4
In each of the above formulas, the symbol A represents cis-vinylene or ethylene, the symbol B represents trans-vinylene or ethylene, the symbol Y represents hydroxy or hydrogen, the symbol R represents hydrogen or methyl, the symbol Z represents hydrogen or methyl, the symbol Ar represents phenyl, fluorophenyl, chlorophenyl, methylphenyl, ethylphenyl, methoxyphenyl, ethoxyphenyl, biphenyl or trifluoromethylphenyl and the symbol G represents CHjAr, CHjOAr or CRZ(CH2)3CH3·
Especially preferred compounds are as follows:
Class 1, N-(tetrazol-5-yl) 9-oxo-ll-alpha, 15-alphabishydroxy-16-phenyl-16-omega-tetranor-5-cis-prostenamide; Class 2, N-(tetrazol-5-yl) 9-oxo-ll-alpha, 15-alphab i shyd roxy-16-phenoxy-16 -omeg a-tet r anor-13-trans-prostenamide; and Class 3, N-(tetrazol-5-yl) 9-oxo-ll-alpha,
-alpha-bishydroxy-5-cis-13-trans-prostadienamide.
In addition there is contemplated the PGF type compounds corresponding to the three classes above and the pharmacologically acceptable salts, the acidic tetrazole moiety being neutralized.
Each class of N-(tetrazole) prostaglandin carboxamides is synthesized from a similar class of 11,15-bis(hydroxyl protected) or ll-desoxy-15-(hydroxyl protected) PGF compounds. This generic starting material has the same basic structure for all the classes and includes any arrangement of bond type at the C5-C6 and C13-C14 positions which relate to the elements A and B of formulae 1, 2 and 3. In other words, it is the (11),15hydroxyl protected PGF compound corresponding to the Generic Formula (4) above. Differentiation of the basic structure according to class is determined by the identity of the terminus of the bottom side chain of the respective starting materials. Thus the starting material for class 1 has the substitution 16-aryl-16omega-tetranor on the above basic PGF structure; the starting material for class 2 has the substitution 16aryloxy-16-omega-tetranor; and the starting material for class 3 has the 15-n-pentyl, 2-hexyl or 2-methyl-2hexyl substitution on the bottom side chain of the above basic PGF structure. These structures are shown on Chart 1 and are Fl, F2 and F3 respectively.
The starting material PGF compounds for each of the classes are known; the characteristics of the 11-hydroxy starting materials are reported in U.S.
4,024,179; U.S. 3,887,589; U.S. 4,011,262;
U.S. 4,036,832; U.K. patent No. 1,324,737 B. J. Mayerlein, et al. Prostaglandins, £, 143 (1973) and E. J. Corey, et. al., J. Amer. Chem. Soc. 93, 1491 (1971) and the characteristics of the 11-desoxy starting materials are reported in . 37106 -r w· Ger. Offenlegungsschrift 2,548267, P. Crabbe, et. al., Tet. Let. 1972, 1123 and W. Lipmann, Prostaglandins, T_ 231 (1974).
The conversion of starting materials into the classes of products of the invention is illustrated by Scheme A. To transform a starting material into a member of a class of compounds of the invention, the C-l carboxylic acid group is first converted into a C-l N-(tetrazol-5-yl) carboxamide group (step 1, Scheme A). Then this N-(tetrazole) carboxamide PGF intermediate is oxidized with Jones reagent to make the corresponding PGE intermediate which is deprotected by removing the 15-mono or 11,15-bis hydroxyl protecting (R') groups (step 2.1, Scheme A) to make an N-(tetrazole) carboxamide prostaglandin of formula 1,2 or 3. Alternatively a PGF type of compound corresponding to PGE compound of formula 1,2 or 3 may be prepared by simple cleavage of the C-ll and/or C-15 hydroxyl (R') protecting groups of the N-(tetrazole) carboxamide intermediate.
Chart 1
STARTING MATERIALS FOR THE VARIOUS CLASSES
R'O.
(THPO) (H)
OH
(THPO)
Fl, starting material for class 1, X is -COOH
OH
P2, starting material for class 2, x is -COOH
OH
(H) R'O (THPO)
Η Η Η H C-A-C-C-C-X Η Η Η H
Η Η Η Η Η H B-C-C-C-C-C-CH s Ζ Η Η Η H
P3, starting material for class 3, X is -COOH
Scheme A
Step 1. formation of the N-(tetrazol-5-yl)carboxamide group
1. CDI reagent
FI, P2 or F3 :
2. anhydrous 5-AT reagent
FI
F2
F3 wherein X is
H
JI—N -CONHCk || ^N—N
Step 2.1. oxidation with Jones reagent and THP cleavage
Fl, F2 or F3, X= -CONHI <3
1,2,3 cr°3 H2SO4 2. CH,CO„H
h2o ‘ 1. Formula 1, starting material is Fl 2. Formula 2, starting material is F2 3. Formula 3, starting material is F3
Step 2.2 cleavage of the THP protecting group to make PGF type compounds
Fl,
F2 or F3, X = CONHC^N-1 ch3cooh h2o
1,2,3
1. PGF compound corresponding to Formula 1, starting material is Fl
2. PGF compound corresponding to Formula 2, starting material is F2
3. PGF compound corresponding to Formula 3, starting material is F3
Reaction Steps 2.1 and 2.2 which embrace cleavage of the C-ll and/or C-15 hydroxyl protecting groups and oxidation of the C-9 hydroxyl to a C-9 oxo (ketone) group are common transformations and are well-known in the art of prostaglandin chemistry. Equivalent methods for C-9 hydroxyl oxidation and for C-ll and/or C-15 hydroxyl protection are also well-known in the art and are applicable here. Prostaglandin researchers have found that selective oxidation methods such as the Pfitzner-Moffett oxidation with dimethyl sulfoxide and dicyclohexylcarbodiimide and the Collins oxidation with chromium trioxidepyridine complex in methylene chloride may also be used to perform the hydroxyl to ketone oxidation. They have also publicized the many methods and groups available for the protection/deprotection of the hydroxyl groups at positions C-ll and/or C-15 of a prostaglandin. Such mild agent labile protecting groups are indicated by R'. The tetrahydropyranyl group is also shown as the preferred group. Some other common mild agent labile protecting groups having utility in the present invention are dimethyl-t-butyl silyl which may be removed with tetra-nbutyl ammonium fluoride or aqueous acetic acid and 1-methoxyethylen-l-yl which is analogous to tetrahydropyran-2-yl.
Step 1 is novel in that it allows the preparation of a C-l amide having an acidic group as a substituent.
The import of this construct is the fact that the prior art teaches the biologically critical invariance of the C-l acidic group, C-9 functionality distance while the compounds of the present invention have in fact extended the distance by the length of two of the atoms of the amide group. The N-(tetrazol-5-yl)carboxamide group can be prepared from the carboxylic acid group by first forming a carboxylic acid derivative having an easily displacable leaving group and then performing the amidation with 5-amino tetrazole (5-AT reagent).
Any leaving group which can be attached to the prostaglandin intermediate (Fl, F2, F3 Chart 1) carboxyl group without destroying the rest of the molecule may be used in the preparation. Some typical leaving groups and the leaving group reagents used to make them include pivaloyloxy/pivaloyl halide which will make the mixed anhydride derivative and ethoxyformyloxy/ethoxyformyl halide which will make the carbonate derivative.
The preferred leaving group is imidazol-l-yl which makes an acyl imidazole intermediate. To prepare the
N-(tetrazol-5-yl) carboxamide group through the intermediacy of an acyl imidazole group, one first reacts
4817S the prostaglandin carboxylic acid starting material (FI,
F2 or F3) with the leaving group reagent 1,1-carbonyl diimidazole in a polar, aprotic solvent such as dimethylformanide, diethylformamide, acetonitrile, tetrahydrofuran or dimethyl sulfoxide to form in situ the acyl imidazole intermediate. The imidazol-l-yl group attached to the C-1 carbonyl is then directly displaced with 5-AT reagent to form the desired N-(tetrazol-5-yl) carboxamide.
A range of reaction temperatures may be employed to both form and displace the acyl imidazole. This range runs from ambient temperature to 120°C and it is convenient to conduct the reaction at about 90°C or reflux.
After forming the N-(tetrazol-5-yl) carboxamide group, reaction step 2.1 is performed by whioh a compound of Formula 1, 2 or 3 is prepared or reaction step 2.2 is performed by which a PGF type of compound is prepared.
Alternatively, the N-(tetrazole) prostaglandins of each class may be synthesized directly from a corresponding PGE or PGF compound of the formula
Η Η Η H C-A-C-C-C-COOH Η Η Η H
H
B-C-G
HO wherein Α,Υ,Β and G are as defined above and M is oxo or H^’OH. In this route, the PGE or PGF acid is reacted using the method of formation of the N-(tetrazol5-yl) carboxamide group given in Step 1 above to directly produce an N-(tetrazole)prostaglandin carboxamide of Formula 1,2,3 above or the corresponding PGF carboxamide. The procedure followed is that of Step 1 provided that if M ia to be oxo, no basic reagent is used.
In numerous in vivo and in vitro tests, it has been established that the three classes of prostaglandin compounds of the present invention exhibit extreme selectivity. Their biological achievement is the diminution of many of the physiological activities of the natural prostaglandins while maintaining activity in one area. The tests which allow such determination of selectivity include among others, a test for effect on isolated smooth muscle from guinea pig uterus, effect on dog blood pressure, inhibition of histamine induced broncho-constriction in the guinea pig, inhibition of cold, stress-induced ulceration in the rat, antisecretory activity in the dog and diarrheal effect in the mouse.
After comparison to the responses caused by natural prostaglandin in the same tests, the physiological responses caused by the three classes experimental prostaglandins in these tests are helpful in determining their usefulness for the treatment of natural and pathological malconditions. Based upon such comparison, the prostaglandins of Class 1 of the invention have utility as selective antiulcer agents, those of Class 2 have utility as fertility control agents, those of Class 3 wherein R is methyl or hydrogen and Z is hydrogen have utility as bronchodilator agents and those of Class 3 wherein both R and Z are methyl have utility as fertility control agents. Biological test observations for the prostaglandins of Class 1 show that they have potent antiulcer activity while having diminished hypotensive, uterine smooth muscle, diarrheal and bronchodilator activities compared to the test standard natural prostaglandin, PGEj. The same type of observations show that the prostaglandins of Class 3 having R as methyl or hydrogen and Z as hydrogen exhibit potent
17S bronchodilator activity and diminished uterine smooth muscle, hypotensive, antiulcer and diarrheal activities. Likewise the prostaglandins of Class 2 exhibit potent uterine smooth muscle activity and diminution of such determined activities as hypotensive activity, diarrheal activity and bronchodilator activity.
The 3 classes of prostaglandins of this invention can be used in a variety of pharmaceutical formulations which contain the prostaglandin, or its pharmaceutically acceptable salts. They may be administered in the same manner as natural prostaglandins by a variety of appropriate routes, such as intravenous, oral and topical including aerosol, intravaginal, intra- and extraamniotic and intranasal among others. Obviously the selective activity of the particular class of prostaglandins of the invention and their intended use will determine the route to be used. For instance the appropriate routes for the Class 2 prostaglandins are intravenous, oral, intravaginal and intra- and extra-amniotic while the appropriate routes for the Class 3 bronchodilator prostaglandins are aerosol, intranasal, oral and intravenous.
For pharmaceutical formulation and for solid compounding of the 3 classes of prostaglandins the useful, pharmacologically acceptable salts of the acidic tetrazole moiety are those with pharmacologically acceptable metal cations, amine cations, or quaternary ammonium cations.
Especially preferred metal cations are those derived from the alkali metal, e.g., lithium, sodium and potassium, and from the alkaline earth metal, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron, are within the scope of this invention.
Pharmacologically acceptable amine cations are those derived from primary, secondary, or tertiary amines. Examples of suitable amines are methyiamine, dimethylamine, triethylamine, ethylamine, benzylamine, alpha-phenylethylamine, beta-phenylethylamine, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, and piperazine as well as amines containing water-solubilizing or hydrophilic groups, e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, galactamine, N-methylglucosamine, ephedrine, phenylephrine, epinephrine and procaine.
Examples of suitable pharmacologically acceptable quaternary ammonium cations are tetramethylammonium, tetraethylammonium, benzyltrimethylammonium and phenyltriethylammonium.
The 3 classes of prostaglandins of this invention can be used in a variety of pharmaceutical preparations which contain the compound or a pharmacologically acceptable salt thereof, and they may be administered by several routes as described above. Although the particular dose, formulation and route of administration are dependent upon each patient's unigue condition and the wisdom of his attending physician, the guidelines set forth infra for the classes of prostaglandins of the present invention describe the usefulness of Class 1 as antiulcer agents, of Class 2 as fertility control agents, of Class 3 wherein R is hydrogen or methyl and Z is hydrogen as bronchodilator agents, and of Class 3 wherein both R and Z are methyl as fertility control agents.
The prostaglandins of Class 1 are useful as antiulcer agents. For treatment of peptic ulcers, these drugs are appropriately administered orally in the form of aqueous suspensions, ethanolic solutions or preferably in the form of capsules or tablets containing 0.001 to 0.10 mg/kg of prostaglandinsper dose with up to 12 doses per day.
For induction of abortion, the prostaglandins of Class 2 and of Class 3 wherein both R and Z are methyl may be orally administered in appropriately formulated tablets, aqueous suspensions or alcoholic solutions containing 0.05-5 mg, of prostaglandin par dose with 1-7 doses per day being employed. For intravaginal administration a suitable formulation would be lactose tablets or an impregnated tampon containing about 0.1-10 mg of prostaglandin per dose with 1-7 doses being employed. For intra-amniotic administration a suitable formulation would be an aqueous solution containing the prostaglandin at 0.05-5 mg/dose vzith 1-7 doses being employed. For extra-amniotic administration a suitable formulation would be an aqueous solution containing the prostaglandin at 0.01-1 mg/dose vzith 1-5 doses being employed. Alternatively, the prostaglandins of Class 2 and of Class 3 wherein both R and Z are methyl can be infused intravenously for induction of abortion at doses of 0.05-50 microgram of prostaglandin per minute for a period of from about 1-24 hours.
Another use for the prostaglandins of Class 2 and of Class 3 wherein both R and Z are methyl is an inducer of labor. For this purpose an ethanol-saline solution of the prostaglandins is employed for an intravenous infusion in the amount of from 0.1-10 microgram/ kg/min of prostaglandin for 1-24 hours. Another use for the prostaglandins of Class 2 and Class 3 wherein both R and Z are methyl is fertility control. For this purpose a tablet is employed for intravaginal or oral administration containing 0.1-10 mg of prostaglandin per dose with 1-7 doses being employed at or following the expected day of menstruation. For synchronization of the estrous cycle of pigs, sheep, covzs or horses, a solution or suspension containing 0.335 30 mg/dose of the prostaglandin administered subcutaneously or intramuscularly from 1-4 days.
The prostaglandins of Class 3 wherein R is hydrogen or methyl and I is hydrogen are useful as bronchodilator agents and to increase nasal patency or accessibility.
An appropriate dosage form for this treatment is solution of the prostaglandin in aqueous ethanol or t-butanol or a suspension thereof employed as an aerosol using an inert gas as a propellant wherein the amount of prostaglandin contained is about 5 to 500 microgram per dose.
To prepare any of the above dosage forms or any of the numerous other forms possible, various reactioninert diluents, excipients or carriers may be employed. Such substances include, for example, water, ethanol, gelatins, lactose, starches, magnesium stearate, talc, vegetable oils, benzyl alcohols, gums, polyalkylene glycols, petroleum jelly, cholesterol and other known carriers for medicaments. If desired, these pharmaceutical compositions may contain auxiliary substances such as preserving agents, wetting agents, stabilizing agents, or other therapeutic agents such as antibiotics.
The following examples are merely illustrative, and in no way limit the scope of the appended claims. The IR spectral data were obtained on a Perkin-Elmer Grating Infrared Spectrometer and are given in microns. The NMR spectral data were obtained on a Varian HA-60 spectrometer Varian is a Registered Trade Mark arid are delta ppn. Melting points are uncorrected and are in °Ctentigrade. TIC measurements were obtained cn silica gel and are recorded as R^ values.
In general, the temperatures of the reactions described in the examples, when unspecified, will be taken to mean ambient or room temperature which varies from 15° to 30’C.
The time requirements of the reactions described in the examples, unless otherwise stated, were determined by monitoring with thin layer chromatography (TLC). The usual TLC system was silica-gel on glass (E. Mercksilica Gel plates, E. Merck, Dormstadt, W. German Merck is a Registered Trade Mark) with
48173 benzene/ether or methanol/chloroform as diluents and vanillin/ethanol or iodine as developers. [Introduction to Chromatography J. M. Bobbitt, A. E. Schwarting, R.J. Gritter, Van Nostrand-Renhold, N.Y. 1968]. As a general rule, the reaction in question was deemed essentially complete when the TLC spot representing the critical starting material disappeared or quit changing appearance
Example 1
N-(Tetrazol-5-yl) 9-alpha-hydroxy-ll-alpha, 15-alpha10 bis-(tetrahydropyran-2-yloxy)-5-cis- 13-trans-prostadienamide (1)
To a solution of 415 mg (0.795 mmole) of 9-alphahydroxy-ll-alpha, 15-alpha-bis-(tetrahydropyran-2yloxy)-5-cis-13-trans-prostadienoic acid (SM) in 10 ml of dry dimethylformamide was added 134 mg (0.825 mmole) of 1,1-carbonyldimidazole. The solution was heated under nitrogen at 95° for 4 hours, then 70 mg (0.825 mole) of anhydrous 5-amino-tetrazole was added. The solution was heated under nitrogen for 1.5 hours at 95° then concentrated by rotary evaporation to provide the crude title compound (1) as a viscous oil weighing 823 mg. Its NMR spectrum (CDCl^) exhibited the following characteristic absorptions (in delta ppm):
.65 - 5.24 (multiplet) - olefinic
4.81 - 4.62 (multiplet) - ^H-0
1.92 (triplet, j = 4 cps) - CH^
Example 2
N-(Tetrazol-5-yl) 9-alpha,11-alpha,15-alpha-trihydroxy
-5-cis-13-trans-prostadienamide (2)
A solution of 200 mg of crude N-(tetrazol-5-yl) 9alpha-hydroxy-11-alpha,15-alpha-bis-(tetrahydropyran-2yloxy)-5-cis-13-trans-prostadienamide (1) in 10 ml of a
63-65 mixture of acetic acid:water was stirred at room temperature for 18 hours under nitrogen; then was concentrated by rotary evaporation. Benzene was added and removed by rotary evaporation (3X). Purification of the crude residue by silica gel column chromatography using mixture of chloroform-ethyl acetate as eluents provided the title compound (2) weighing 6 mg and melting at 168-172® (after reorystallization from ethanol-ether).
TLC Rff was 0.26 (3:2. chloroform:methanol)
Example 3
N-(Tetrazol-5-yl) 9-oxo-ll-alpha,15-alpha-bis(tetrahydropyran-2-yloxy)-5-cis-13-trans-prostadienamide (3)
To a solution, cooled to-20®, of 623 mg (1.06 mmoles) of N-(tetrazol-5-yl) 9-alpha-hydroxy-ll-alpha, 15-alpha-bis-(tetrahydropyran-2-yloxy)-5-cis-13-transprostadienamide (1) in 15 ml of acetone was added 0.38 ml of Jones reagent. The mixture was stirred for 20 minutes then quenched in the cold by 0.38 ml of isopropyl alcohol. The mixture was stirred for 5 minutes then diluted with ethyl acetate (25 ml), washed with water (3 X 5 ml) and saturated brine (5 ml), dried (magnesium sulfate) and concentrated to provide the title compound (3) as a viscous oil weighing 295 mg.
TLC Rff was 0.48 (9:1, methylene chloride:methanol).
Example 4
N-(Tetrazol-5-yl) 9-oxo-ll-alpha,15-alpha-dihydroxy5-cis-13-trans-prostadienamide (4)
A solution of 295 mg of crude N-(tetrazol-5-yl) 9oxo-ll-alpha,15-alpha-bis-(tetrahydropyran-2-yloxy)-5cis-13-trans-prostadienamide (3) in 30 ml of a 65:35 mixture of acetic acid-water was stirred at room temperature under nitrogen for 18 hours. The solution was concentrated by rotary evaporation and benzene was added and concentrated (3X). Purification of the residue by
8 17 S silica gel column chromatography using mixtures of chloroform - ethyl acetate as eluents provided the title compound (4) weighing 22 mg and melting at 162°. Its IR spectrum (KBr) exhibited the following characteristic absorptions (in microns):
.71 (ketone)
.87 (amide)
6.12
.33 (trans olefin)
Example 5
The following additional compounds were prepared using the procedures described by Examples 1 to 4 and by substituting the appropriate starting material
PGF carboxylic acid for compound (SM) in Example 1.
5A. N-(tetrazol-S-yl) 9-oxo-ll-alpha,15-alphadihydroxy-13-trans-prostenamide m.p. - solid NMR (CD3OD) (in delta ppm): 5.76 5.44 (multiplet) transolefin; 1.88 (triplet, j = 4 cps) CHj
5b. N-(Tetrazol-5-yl) 9-oxo-ll-alpha,15-alphadihydroxy-5- cis-16-pheny1-16-omegatetranorprostenamide. m.p. 75-78° NMR (CD30D) (in delta ppm): 7.08 (singlet) CgH5; 5.43-0.17 (multiplet) cis-olefin.
5C. N-(tetrazol-5-yl) 9-oxo-ll-alpha,15-alpha2 5 dihydroxy-13-trans-16-phenyl-16-omegatetranorprostenamide
m.p. - 149-150° IR (KBr) (in microns): 5.67 (ketone),
.83 and 6.10 (amide), 10.28 (trans-olefin).
5D. N-(tetrazol-5-yl) 9-alpha,ll-alpha,15-alphatrihydroxy-5-cis-13-trans-16-phenoxy-16-omegatetranor30 prostadienamide. m.p. - 87-90° IR (KBr) (in microns): 5.97 and 6.25 (amide), 10.35 (trans-olefin).
5E. N-(tetrazol-5-yl) 9-oxo-ll-alpha,15-alphadihydroxy-5- cis-13-trans-16-phenoxy-16-omegatetranorprostadienamide. m.p. 105-107° IR (KBr) (in microns):
.68 (ketone), 5.85 and 6.10 (amide), 10.28 (transolefin).
4817S
The synthesis of the compounds of Examples 1 to 5 demonstrates that the 11-hydroxy prostaglandins of classes 1, 2 and 3 of the invention and the corresponding PGF type compounds may be synthesized using the chemical methods described in Examples 1 through 4 by substituting the appropriate 11,15-bis(tetrahydropyran-2-yl) PGFj ' 13»14-dihydro PGF2 , PGF^ or PGFq wherein the substituent at the C-16 position is phenyl or substituted phenyl for class 1 preparation, phenoxy or substituted phenoxy for class 2 preparation and n-butyl or both methyl and n-butyl for class 3 preparation, for the PGF intermediate labeled (SM) in Example 1, the substituents for the substituted phenyl and phenoxy classes being fluoro, chloro, methyl, ethyl, methoxy, ethoxy, phenyl and trifluoromethyl.
Example 6
N-(Tetrazol-5-yl) 9-alpha-Hydroxy-15-alpha(tetrahydropyran-2-yloxy)-16-phenoxy-16-omegatetranor-13-transprostenamide (6)
To a solution of 0.795 mmole of 9-alpha-hydroxy15-alpha-(tetrahydropyran-2-yloxy)-16-phenoxy-16-omegatetranor-13-trans-prostenoic acid (DSM)in 10 ml of dry dimethylformamide is added 134 mg (0.825 mmole) of
1,1-carbonyldimidazole. The solution is heated under nitrogen at 95° for 4 hours, then 70 mg (0.825 mole) of anhydrous 5-amino-tetrazole is added. The solution is heated under nitrogen for 1.5 hours at 95° and then can be concentrated by rotary evaporation to provide the crude title compound (6).
Example 7
N-(Tetrazol-5-yl) 9-alpha-15-alpha-dihydroxy
16-phenoxy-16-omegatetranor-13-trans-prostenamide 7)
A solution of 200 mg of crude N-(tetrazol-5-yl) 9-alpha-hydroxy-15-alpha-(tetrahydropyran-2-yloxy)-16phenoxy-16-omega-tetranor-13-trans-prostenamide (6) in ml of a 65-35 mixture of acetic acid:water is stirred at room temperature for 18 hours under nitrogen and then is concentrated by rotary evaporation. Benzene is added and removed by rotary evaporation (3X).
Purification of the crude residue by silica gel column chromatography using mixture of chloroform-ethyl acetate as eluents may be employed to purify the title compound (7).
Example 8
N-(Tetrazol-5-yl) 9-oxo-15-alpha-(tetrahydropyran2-y1oxy)-16-phenoxy-16-omeqatetranor-13-trans-prostenamide (8)
To a solution, cooled to -20®, of 1.06 mmoles of N-(tetrazol-5-yl) 9-alpha-hydroxy-15-alpha-(tetrahydro15 pyran-2-yloxy)-16-phenoxy-16-omegatetranor-13-transprostenamide (6) in 15 ml of acetone is added 0.38 ml of Jones reagent. The mixture is stirred for about 20 minutes then quenched in the cold by 0.38 ml of isopropyl alcohol. The mixture is stirred for 5 minutes then it is diluted with ethyl acetate (25 ml), washed with water (3 x 5 ml) and saturated brine (5 ml), dried (magnesium sulfate) and concentrated to provide the title compound (8).
Example 9
N-(Tetrazol-5-yl) 9-oxo-15-alpha-hydroxy16-phenoxy-16-omegatetranor-13-trans-prostenamide (9)
A solution of 295 mg of crude N-(tetrazol-5-yl)9alpha-hydroxy-15-alpha-(tetrahydropyran-2-yloxy)-16phenoxy-16-omegatetranor-13-trans-prostenamide (3) in
ml of a 65:35 mixture of acetic acid-water is stirred at room temperature under nitrogen for 18 hours. The solution is concentrated by rotary evaporation and benzene is then added and removed in the same way (3X). Purification of the residue by silica gel column chroma35 tography using mixtures of chloroform - ethyl acetate as eluents will provide the title compound (9).
The synthesis of the compounds of Examples 6 through 9 demonstrates that the 11-desoxy prostaglandins of classes 1, 2 and 3 of the invention and the corresponding PGF type compounds may be synthesized using the chemical methods described in Examples 6 through 9 by substituting the appropriate ll-desoxy-15-tetrahydropyran-2-yl PGF2 , 13,14-dihydro PGF2 , PGF1 or PGFQ starting material wherein the substituent at the C-16 position is phenyl or substituted phenyl for class 1 preparation, phenoxy or substituted phenoxy for class 2 preparation and n-butyl or both methyl and n-butyl for class 3 preparation, for the PGF intermediate labeled (DSM) in Example 6, the substituents for the substituted phenyl and phenoxy classes being fluoro, chloro, methyl, ethyl methoxy, ethoxy, phenyl and trifluoromethyl.
Example 10
N-(Tetrazol-5-yl) 9-alpha-hydroxy-ll-alpha, 15-alpha-bis(tetrahydropyran-2-yloxy)-16,16-dimethyl-5-cis13-trans-prostadienamide (10)
To a solution of 0.795 mmole of 9-alpha-hydroxyll-alpha, 15-alpha-bis-( tetrahydropyran-2-yloxy )-16 , 16dimethyl-5-cis-13-trans-prostadienoic acid (RSM) in 10 ml of dry dimethylformamide is added 134 mg (0.825 mmole) of 1,1-carbonyldimidazole. The solution is heated under nitrogen at 95® for 4 hours, then 70 mg (0.825 mole) of anhydrous 5-amino-tetrazole is added.
The solution is heated under nitrogen for 1.5 hours at 95® then concentrated by rotary evaporation to provide the crude title compound (10) as viscous oil.
Example 11
N-(Tetrazol-5-yl 9-alpha,ll-alpha,15-alpha-trihydroxy16,16-dimethyl-5-cis-13-trans-prostadienamide (11)
A solution of 200 mg of crude N-(tetrazol-5-yl)
9-alpha-hydroxy-ll-alpha,15-alpha-bis-(tetrahydropyran2-yloxy)-16,16-dimethyl-5-cis-13-trans-prostadienamide (10) in 10 ml of a 65-35 mixture of acetic acid:water is stirred at room temperature for 18 hours under nitrogen; then is concentrated by rotary evaporation. Benzene is added and removed by rotary evaporation (3X). Purification of the crude residue by silica gel column chromatography using mixture of chloroform-ethyl acetate as eluents may be carried out to provide the title compound (11).
Example 12
N-(Tetrazol-5-yl) 9-oxo-ll-alpha,15-alpha-bis10 (tetrahydropyran-2-yloxy)-16,16-dimethyl-5cis-13-trans-prostadienamide (12)
To a solution, cooled to -20°, of 623 mg (1.06 mmoles) of N-(tetrazol-5-yl) 9-alpha-hydroxy-ll-alpha,15-alpha-bis(tetrahydro-pyran-2-yloxy)-16,16-dimethyl-5-cis-13-trans15 prostadienamide (10) in 15 ml of acetone is added 0.38 ml of Jones reagent. The mixture is stirred for about 20 minutes then quenched in the cold by 0.38 ml of isopropyl alcohol. The mixture is stirred for 5 minutes then diluted with ethyl acetate (25 ml), washed with water (3 X 5 ml) and saturated brine (5 ml), dried (magnesium sulfate) and concentrated to provide the title compound (12).
Example 13
N-(Tetrazol-5-yl) 9-oxo-ll-alpha,15-alpha-dihydroxy25 16,16-dimethyl-5-cis-13-trans-prostadienamide (13)
A solution of 295 mg of crude N-(tetrazol-5-yl)
9-oxo-11-alpha,15-alpha-bis-(tetrahydropyran-2-yloxy)16,16-dimethyl-5-cis-13-trans-prostadienamide (12) in 30 ml of a 65:35 mixture of acetic acid-water is stirred at room temperature under nitrogen for 18 hours. The solution is concentrated by rotary evaporation and benzene is added and concentrated (3X). Purification of the residue by silica gel column chromatography using mixtures of chloroform - ethyl acetate as eluents may be carried out to provide the title compound (13).
The synthesis of the compounds of Examples 10 through 13 demonstrates that the 11-hydroxy or 11-desoxy
16,16-dimethyl prostaglandins of the invention and the corresponding PGF type compounds may be synthesized using the chemical methods described in Examples 10 through 13 by substituting the appropriate 11,15bis(tetrahydropyran-2-yl) or ll-desoxy-15-(tetrahydropyran-2-yl)-16,16-dimethyl PGF2 ' 13,14-dihydro PGF2 , PGFj or PGFq for the PGF intermediate labeled (RSM) in Example 10.
Claims (6)
1. A compound of the formula M Η Η Η H H N-N -C—A—C—C—C—CONH Η Η Η H N_N B—C—G HO or a pharmacologically acceptable salt thereof, wherein:5 M is oxo or ΌΗ A is ethylene or cis-vinylene; B is ethylene or trans-vinylene; Y is hydrogen or hydroxy; 10 G is CH 2 Ar, CH 2 OAr or CRZ(CHj) 3 CH 3 ; Ar is phenyl, fluorophenyl, chlorophenyl, methyIphenyl, ethyl phenyl, methoxyphenyl, ethoxyphenyl, biphenyl or trifluoromethylphenyl; R is hydrogen or methyl; and 15 Z is hydrogen or methyl.
2. A compound as claimed in claim 1, wherein M is oxo. A compound as claimed in claim 1, wherein M is χ A H ‘OH
3. 4. Ν-(tetrazol-5-yl)-9-oxo-ll-alpha, 15-alpha-bishydroxy-16-phenyl-16-omegatetranor-5-cis-prostenamide.
4. 5. N-(tetrazol-5-yl)-9-oxo-ll-alpha, 15-alpha-bis-hydroxy-16-phenoxy-16-omegatetranor-5-cls-135 trans-prostadlenamide.
5.
6. N-(tetrazol-5-yl)-9-oxo-ll-alpha, 15-alpha-bis-hydroxy5-cis-13-trans-prostadienamide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86956978A | 1978-01-16 | 1978-01-16 | |
US89373178A | 1978-04-05 | 1978-04-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE790060L IE790060L (en) | 1979-07-16 |
IE48175B1 true IE48175B1 (en) | 1984-10-17 |
Family
ID=27128123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE60/79A IE48175B1 (en) | 1978-01-16 | 1979-01-15 | N-(tetrazol-5-yl)prostaglandin carboxamides |
Country Status (28)
Country | Link |
---|---|
JP (1) | JPS54100378A (en) |
AR (1) | AR222817A1 (en) |
AT (1) | AT367755B (en) |
AU (1) | AU507853B2 (en) |
CA (1) | CA1152502A (en) |
CH (1) | CH635833A5 (en) |
DD (1) | DD141155A5 (en) |
DE (1) | DE2901476C3 (en) |
DK (1) | DK523378A (en) |
ES (1) | ES482421A1 (en) |
FI (1) | FI790120A (en) |
FR (1) | FR2414503A1 (en) |
GB (1) | GB2012272B (en) |
GR (1) | GR72747B (en) |
IE (1) | IE48175B1 (en) |
IL (1) | IL56433A (en) |
IN (1) | IN150279B (en) |
IT (1) | IT1110992B (en) |
LU (1) | LU80789A1 (en) |
NL (1) | NL7900292A (en) |
NO (1) | NO790122L (en) |
NZ (1) | NZ189377A (en) |
PH (3) | PH15031A (en) |
PL (1) | PL117869B1 (en) |
PT (1) | PT69076A (en) |
SE (1) | SE427657B (en) |
SU (1) | SU831071A3 (en) |
YU (1) | YU4579A (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE788209A (en) * | 1971-09-01 | 1973-02-28 | Pfizer | TETRAZOYL DERIVATIVES OF NATURAL PROSTAGLANDINS |
DD118856A5 (en) * | 1972-11-08 | 1976-03-20 | ||
IE43462B1 (en) * | 1975-06-23 | 1981-03-11 | Pfizer | Substituted tetranorprostaglandins |
DE2559093C3 (en) * | 1975-12-30 | 1981-12-24 | Pfizer Inc., 10017 New York, N.Y. | 2-dearboxy-2- [tetrazol-5-yl] -11-deoxy-ω-pentanorprostaglandins of the E or F series and their C ↓ 15 ↓ epimers |
US4404372A (en) * | 1977-06-13 | 1983-09-13 | Pfizer Inc. | 15-Substituted-ω-pentanorprostaglandin derivatives |
-
1978
- 1978-11-23 DK DK523378A patent/DK523378A/en not_active Application Discontinuation
- 1978-11-23 IN IN841/DEL/78A patent/IN150279B/en unknown
- 1978-12-27 PL PL1978212183A patent/PL117869B1/en unknown
- 1978-12-27 DD DD78210198A patent/DD141155A5/en unknown
- 1978-12-27 SU SU782715902A patent/SU831071A3/en active
-
1979
- 1979-01-11 YU YU00045/79A patent/YU4579A/en unknown
- 1979-01-12 CA CA000319536A patent/CA1152502A/en not_active Expired
- 1979-01-12 PH PH22056A patent/PH15031A/en unknown
- 1979-01-12 JP JP286979A patent/JPS54100378A/en active Pending
- 1979-01-15 GR GR58098A patent/GR72747B/el unknown
- 1979-01-15 IL IL56433A patent/IL56433A/en unknown
- 1979-01-15 FI FI790120A patent/FI790120A/en unknown
- 1979-01-15 CH CH38079A patent/CH635833A5/en not_active IP Right Cessation
- 1979-01-15 AU AU43359/79A patent/AU507853B2/en not_active Ceased
- 1979-01-15 NZ NZ189377A patent/NZ189377A/en unknown
- 1979-01-15 NL NL7900292A patent/NL7900292A/en not_active Application Discontinuation
- 1979-01-15 AT AT0027579A patent/AT367755B/en not_active IP Right Cessation
- 1979-01-15 FR FR7900857A patent/FR2414503A1/en active Granted
- 1979-01-15 SE SE7900353A patent/SE427657B/en not_active IP Right Cessation
- 1979-01-15 NO NO790122A patent/NO790122L/en unknown
- 1979-01-15 IE IE60/79A patent/IE48175B1/en unknown
- 1979-01-15 LU LU80789A patent/LU80789A1/en unknown
- 1979-01-15 PT PT69076A patent/PT69076A/en unknown
- 1979-01-15 GB GB791428A patent/GB2012272B/en not_active Expired
- 1979-01-15 IT IT19290/79A patent/IT1110992B/en active
- 1979-01-16 AR AR275174A patent/AR222817A1/en active
- 1979-01-16 DE DE2901476A patent/DE2901476C3/en not_active Expired
- 1979-07-11 ES ES482421A patent/ES482421A1/en not_active Expired
- 1979-11-19 PH PH23299A patent/PH15653A/en unknown
- 1979-11-19 PH PH23301A patent/PH15643A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4024179A (en) | Substituted ω-pentanorprostaglandins | |
CH648286A5 (en) | PROSTAGLAND DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES. | |
DE2355540C2 (en) | 16-phenoxy-ω-tetranorprostaglandin derivatives | |
US4169895A (en) | Antisecretory 16,16-dimethyl-17-oxaprostaglandins | |
JPS5929193B2 (en) | 4,4,5,5-tetradehydro PGF1 | |
JPS5829759A (en) | 11-desoxy-16-aryloxy-omega-tetranorprostaglandins | |
WO1983004021A1 (en) | 2,3,4-trinor-1,5-inter-m-phenylene-prostacycline-i2 analogues, process for the preparation thereof and pharmaceutical compositions containing the same | |
IE48175B1 (en) | N-(tetrazol-5-yl)prostaglandin carboxamides | |
US4091015A (en) | 15-Substituted prostanoic acids | |
EP0025687B1 (en) | 15-methanesulfonamidoprostaglandin derivatives, pharmaceutical compositions thereof and process therefor | |
FI58116B (en) | FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT AKTIVA PARABIFENYLESTRAR AV PROSTAGLANDINSERIERNA E OCH F | |
US4404372A (en) | 15-Substituted-ω-pentanorprostaglandin derivatives | |
DE2606051A1 (en) | 2,2-DIFLUORO-PROSTAGLANDIN-E, -F LOW ALPHA, -F LOW BETA, -A AND -B ANALOGA AND METHOD FOR THEIR PRODUCTION | |
FR2515642A1 (en) | NOVELS (11R) -11-DEOXY-11-ALKYL-6-OXO-PROSTAGLANDINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
US4292444A (en) | Sulfonyl prostaglandin carboxamide derivatives | |
US4342868A (en) | 2-Descarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-17-(2-furyl)-ω-trisnorprostaglandin E2 | |
EP0046597B1 (en) | 2,4-diazabicyclo(3.3.0)octane-3-one derivatives, their preparation and their pharmaceutical formulation | |
EP0022443B1 (en) | N-alkanesulfonyl 16,16-dimethyl-17-oxaprostaglandin carboxamides | |
CS208109B2 (en) | Method of preparation of the new n-/tetrazol-5-yl/-prostaglandicarboxamids | |
IE48926B1 (en) | N-alkanesulfonyl 16,16-dimethyl-17-oxaprostaglandin carboxamides | |
US3989736A (en) | Prostaglandin 5-indanyl esters | |
US4244887A (en) | Substituted ω-pentanorprostaglandins | |
KR840001569B1 (en) | Process for the preparation of prostaglandine derivatives of 2-pge2 2-pgf2 series | |
DE2641091A1 (en) | PROSTAGLANDIN ANALOGS AND METHOD FOR PRODUCING THEREOF | |
WO1992015594A1 (en) | Benzamide derivatives |